Redchip
Oct 20, 1:16 PM
BioVie (
$BIVI ): Phase 2 Parkinson’s Data Show Bezisterim Improved Motor and Non-Motor Symptoms
BioVie presented Phase 2 SUNRISE-PD results at the 2026 American Neurological Association Annual Meeting. In the 57-patient trial, patients with higher baseline inflammation showed statistically significant improvements in both motor and non-motor symptoms versus placebo. Across all patients, those on bezisterim were 6.25 times more likely than placebo patients to achieve clinically meaningful improvement (25% vs. 4%). Bezisterim was well tolerated, with no severe or serious adverse events reported, and BioVie said the findings support the design of a potential Phase 3 trial.
Full press release: https://redchip.news/3VVduTq
